Metabolic Syndrome (NCEP ATP III)

About Metabolic Syndrome (NCEP ATP III)

Metabolic syndrome is a clustering of metabolic abnormalities, abdominal obesity, hypertension, dysglycemia, hypertriglyceridemia, and low HDL cholesterol, that collectively identify individuals at substantially elevated risk of type 2 diabetes and atherosclerotic cardiovascular disease. The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) introduced the most widely used diagnostic criteria in 2001, with a 2004 revision that lowered the fasting glucose threshold from 110 to 100 mg/dL to align with the American Diabetes Association's updated definition of impaired fasting glucose. The diagnosis is made when 3 or more of 5 criteria are met.

What the calculator measures

The NCEP ATP III calculator returns the number of criteria met (0 to 5) and flags whether metabolic syndrome is present (3 or more criteria). Each criterion reflects a different facet of the insulin resistance syndrome that underlies metabolic syndrome: abdominal obesity reflects visceral adiposity; elevated blood pressure reflects endothelial dysfunction and sodium retention; elevated fasting glucose reflects hepatic insulin resistance; hypertriglyceridemia reflects overproduction of VLDL particles; and low HDL reflects impaired reverse cholesterol transport. The combination of these abnormalities is more predictive of cardiovascular events than any single component.

How the formula works

The 2004 revised NCEP ATP III criteria are: 1. Abdominal obesity: Waist circumference ≥102 cm (40 in) in men or ≥88 cm (35 in) in women. (Some ethnic-specific lower thresholds exist; the IDF suggests ≥90 cm in Asian men and ≥80 cm in Asian women.) 2. Blood pressure: Systolic ≥130 mmHg or diastolic ≥85 mmHg, or on antihypertensive medication. 3. Fasting glucose: ≥100 mg/dL, or on glucose-lowering medication. 4. Triglycerides: ≥150 mg/dL, or on fibrate or nicotinic acid. 5. HDL cholesterol: <40 mg/dL in men or <50 mg/dL in women, or on fibrate or nicotinic acid. Each criterion is binary (present or absent); the diagnosis requires 3 or more to be present. Treatment with medication that lowers a given parameter (e.g. antihypertensives for blood pressure, metformin for glucose) counts as meeting that criterion, because the underlying abnormality persists even if the medication normalizes the measured value.

Interpretation

The presence of metabolic syndrome confers approximately a 2-fold increase in cardiovascular events and a 5-fold increase in type 2 diabetes over 5 years. The risk increases with the number of criteria met: a person meeting all 5 criteria has roughly 5 times the cardiovascular risk of a person meeting 0 criteria. The 2018 ACC/AHA cholesterol guideline lists metabolic syndrome as a 'risk-enhancing factor' that supports statin therapy in intermediate-risk patients. Metabolic syndrome is also a major diagnostic criterion for non-alcoholic fatty liver disease (NAFLD), which shares its underlying pathophysiology.

Clinical use

The NCEP ATP III criteria are the most widely used in U.S. clinical practice and in research, in part because they require only routinely measured parameters (waist circumference, blood pressure, fasting glucose, triglycerides, HDL) and do not require a fasting insulin measurement (which is less standardized). The criteria are endorsed by the American Heart Association, the National Heart, Lung, and Blood Institute, the American Diabetes Association, and the Endocrine Society. They form the basis for the metabolic syndrome component of the ASCVD risk-enhancing factors in the 2018 ACC/AHA cholesterol guideline.

Limitations

The NCEP ATP III criteria have several limitations. First, the waist circumference thresholds are derived from predominantly white populations and may underestimate risk in Asian populations; the IDF and AACE criteria use lower thresholds (90 cm in Asian men, 80 cm in Asian women). Second, the criteria do not include insulin resistance directly, which some argue is the central abnormality. Third, the binary threshold approach (e.g. glucose ≥100 vs <100) ignores the continuous dose-response relationship between each parameter and risk. Fourth, the criteria do not distinguish between visceral and subcutaneous abdominal fat; imaging-based assessments (CT, MRI) can quantify visceral fat more precisely. Fifth, the criteria may miss metabolic syndrome in non-obese individuals with insulin resistance (the so-called 'metabolically obese, normal weight' phenotype).

Comparison with IDF criteria

The International Diabetes Federation (IDF) 2005 criteria require central obesity (defined as waist circumference ≥94 cm in Europid men or ≥80 cm in Europid women, or higher BMI if waist not available) as a mandatory criterion, plus 2 of the other 4 NCEP ATP III criteria. The IDF uses lower waist thresholds for some ethnic groups (90 cm in Asian men, 80 cm in Asian women). The IDF criteria are more restrictive than NCEP ATP III (which allows any combination of 3 of 5), but they capture the central role of visceral obesity in metabolic syndrome. In practice, the two criteria agree in the majority of patients; discrepancies are most often at the boundary of central obesity.

How to use the result

A result of 3 or more criteria confirms metabolic syndrome. The clinical response should address each abnormality: weight loss (especially visceral fat reduction through diet and exercise), Mediterranean or DASH diet, aerobic exercise (≥150 min/week of moderate intensity), resistance training (2-3 days/week), blood pressure control, glycemic control (with metformin if prediabetes is present), and lipid management with statins and fibrates as needed. Patients with metabolic syndrome should be screened for type 2 diabetes (fasting glucose or HbA1c), non-alcoholic fatty liver disease (FIB-4 or NAFLD fibrosis score), and obstructive sleep apnea (which is strongly associated with metabolic syndrome).